Aardvark Therapeutics, Inc. (AARD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.38-6.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AARD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 21.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -64.6% |
Growth built into the price is above our model estimate.
The price assumes 85.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AARD — officer change
Dated 2026-06-12
The company provided retention bonuses to its CFO/COO and CMO.
Why it matters: The retention bonus shows that leaders are stable during a hard time.
Supportive ifPublic announcement of the retention bonus deal with the CFO.
Worry ifNo news or bad news about the CFO's role or retention.
Why it matters: Updates on cash will show if the company can pay for operations and trials.
Worry ifAardvark has cash reserves over $70 million. This shows strong liquidity.
Less concerning ifCash reserves drop below $60 million. This raises worries about funding.
Why it matters: This guidance will clarify the path forward for ARD-101 after the FDA hold. Investors need to know if the program can resume.
Watch forAardvark provides a clear update on the ARD-101 program in Q2 2026.
Also watch forNo update or further delays in guidance regarding ARD-101.
Why it matters: The retention bonus may change the CFO's commitment. This could impact the company's performance.
Supportive ifThe CFO leads projects that help financial results. They also make operations work better.
Worry ifThe CFO's performance may not improve. This could cause more operational problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$470 on $10,000 · ±4.7% | How much price usually moves either way. |
| Bad day | $1,000 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,001 loss on $10,000 · 80.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash will show financial health and if operations can continue.
Worry ifCash is over $70 million, which shows there is enough money to operate.
Less concerning ifCash drops below $70 million. This raises concerns about funding operations.
Why it matters: The health care sector is maturing. A return to strong growth could benefit Aardvark's outlook.
Supportive ifHealth care sector revenue growth exceeds 10% year over year.
Worry ifSector revenue growth keeps slowing down below 10% each year.
Why it matters: The results will guide the next steps for ARD-101, which is critical for its future.
Supportive ifManagement will share unblinded data from HERO and OLE trials in Q3 2026.
Worry ifNo data is released. The data shows no safety or effectiveness gains.